Dengue Pdf

The incidence of dengue has grown dramatically around the world in recent decades, with cases reported to WHO increased from 505 430 cases in 2000 to 5.2 million in 2019. A vast majority of cases are asymptomatic or mild and self-managed, and hence the actual numbers of dengue cases are under-reported. Many cases are also misdiagnosed as other febrile illnesses (1).

One modelling estimate indicates 390 million dengue virus infections per year of which 96 million manifest clinically (2). Another study on the prevalence of dengue estimates that 3.9 billion people are at risk of infection with dengue viruses.

Dengue Pdf

DOWNLOAD 🔥 https://tiurll.com/2y3DAD 🔥

The largest number of dengue cases ever reported globally was in 2019. All regions were affected, and dengue transmission was recorded in Afghanistan for the first time. The American Region reported 3.1 million cases, with more than 25 000 classified as severe. A high number of cases were reported in Bangladesh (101 000), Malaysia (131 000) Philippines (420 000), Vietnam (320 000) in Asia.

Mosquitoes can become infected by people who are viremic with DENV. This can be someone who has a symptomatic dengue infection, someone who is yet to have a symptomatic infection (they are pre-symptomatic), but also people who show no signs of illness as well (they are asymptomatic).

The primary mode of transmission of DENV between humans involves mosquito vectors. There is evidence however, of the possibility of maternal transmission (from a pregnant mother to her baby). At the same time, vertical transmission rates appear low, with the risk of vertical transmission seemingly linked to the timing of the dengue infection during the pregnancy. When a mother does have a DENV infection when she is pregnant, babies may suffer from pre-term birth, low birthweight, and fetal distress.

Urbanization (especially unplanned), is associated with dengue transmission through multiple social and environmental factors: population density, human mobility, access to reliable water source, water storage practice etc.

So far one vaccine (Dengvaxia) has been approved and licensed in some countries. However, only persons with evidence of past dengue infection can be protected by this vaccine. Several additional dengue vaccine candidates are under evaluation.

Dengue (pronounced DENgee) fever is a painful, debilitating mosquito-borne disease caused by any one of four closely related dengue viruses. These viruses are related to the viruses that cause West Nile infection and yellow fever.

Most cases in the United States occur in people who contracted the infection while traveling abroad. But the risk is increasing for people living along the Texas-Mexico border and in other parts of the southern United States. In 2014, an outbreak of dengue fever was identified in Hawaii with other outbreaks in 2013 in Brownsville, Texas, and Key West, Fla. The Centers for Disease Control reported about 2,000 total cases in the U.S. and U.S. territories in 2022.

Sometimes, symptoms are mild and can be mistaken for those of the flu or another viral infection. Younger children and people who have never had the infection before tend to have milder cases than older children and adults. However, serious problems can develop. These include dengue hemorrhagic fever, a rare complication characterized by high fever, damage to lymph and blood vessels, bleeding from the nose and gums, enlargement of the liver, and failure of the circulatory system. The symptoms may progress to massive bleeding, shock, and death. This is called dengue shock syndrome (DSS).

Doctors can diagnose dengue infection with a blood test to check for the virus or antibodies to it. If you become sick after traveling to a tropical area, let your doctor know. This will allow your doctor to evaluate the possibility that your symptoms were caused by a dengue infection.

There is no specific medicine to treat dengue infection. If you think you may have dengue fever, you should use pain relievers with acetaminophen and avoid medicines with aspirin, which could worsen bleeding. You should also rest, drink plenty of fluids, and see your doctor. If you start to feel worse in the first 24 hours after your fever goes down, you should get to a hospital immediately to be checked for complications.

The best way to prevent the disease is to prevent bites by infected mosquitoes, particularly if you are living in or traveling to a tropical area. This involves protecting yourself and making efforts to keep the mosquito population down. In 2019, the FDA approved a vaccine called Dengvaxia to help prevent the disease from occurring in adolescents aged 9 to 16 who have already been infected by dengue. But, there currently is no vaccine to prevent the general population from contracting it.

If someone in your home gets dengue fever, be especially vigilant about efforts to protect yourself and other family members from mosquitoes. Mosquitoes that bite the infected family member could spread the infection to others in your home.

Severe dengue is a serious form of the illness. About 1 in 20 people who get sick with dengue will develop severe dengue. It can cause shock, internal bleeding, and even death. People are more likely to develop severe dengue if they have had dengue before, are pregnant, or are infants.

Watch for signs and symptoms of severe dengue. Warning signs usually begin about 24 - 48 hours after your fever has gone away. If you or your family member have these signs, get immediate medical care:

The four dengue viruses are transmitted in tropical countries that circle the globe. All can cause syndromes that are self-limited or severe. The common severe syndrome--dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS)--is characterised by sudden vascular permeability generated by cytokines released when T cells attack dengue-infected cells. Dengue 1 virus became prevalent in Hawaii where it was transmitted by Aedes albopictus, producing a classic virgin soil epidemic, with clinical disease seen largely in adults. In Cuba and Singapore, sequential dengue infections at long intervals produced unusually severe disease in adults. Evidence suggests that enhancing and cross-reactive neutralising antibodies regulate dengue epidemics and disease severity. Classic DHF/DSS arises during initial dengue infections in infants with low circulating amounts of maternal dengue antibodies, an observation that precludes an exclusive causal role for secondary T-cell responses. Here, I review and discuss data on clinical diagnosis and pathophysiology of vascular permeability and coagulopathy, parenteral treatment of DHF/DSS, and new laboratory tests.

Since 2003, and in response to the dengue situation in the Americas, the PAHO/WHO Regional Dengue Program, along with the countries in the Americas, implemented the Integrated Management Strategy for dengue prevention and control in the Americas (IMS-Dengue). This strategy integrates six components; patient care, social communication, environment, integrated vector management, laboratory and epidemiology. The epidemiological surveillance is part of this last component and represents one of the main challenges at Regional level, however, significant achievements are being made in terms of standardization of indicators, which will allow for timely interventions.

In 2023 and until the beginning of December, over 5 million cases and over 5 000 dengue-related deaths have been reported from 86 countries/territories globally. Autochthonous/non-travel associated dengue cases have been reported in Europe from Italy (82) France (43) and Spain (3).

In the French Antilles, Martinique and Guadeloupe are currently experiencing increasing dengue trends and they have entered an epidemic phase (Phase 4; Sante Publique France 23/08/2023). In the beginning of November (Dengue Surveillance Bulletin, 9/11/2023), Sant-Martin and Saint-Barthlemy, transitioned to the epidemic phase (phase 3) after showing increasing trends in dengue cases since October 2023. According to the epidemiologic report published on 7 December, the indicator number of patients presenting with dengue symptoms in Guadeloupe and Martinique has been decreasing, cases with clinical symptoms are increasing in Saint-Martin but it is stable in Saint-Barthelemy. Dengue cases have also been reported in 2023 in Runion (low activity) and in French Guyana, where the activity remains high but stable (1948 cases reported since the beginning of the year and until 23 November 2023). 2351a5e196